TL;DR
This study systematically reviewed 10 randomized controlled trials (RCTs) to evaluate the efficacy and safety of Shexiang Baoxin Pill (SXBXP), a traditional Chinese medicine, for Coronary Slow Flow (CSF). While meta-analysis suggests SXBXP combined with conventional Western medicine (CWM) improves angina symptoms, blood flow markers, and reduces inflammation, the overall quality of evidence is low to very low, necessitating high-quality future research.
What Problem Does This Paper Address?
Coronary Slow Flow (CSF) is a cardiovascular condition characterized by delayed blood flow in the coronary arteries, often presenting with angina pectoris. Despite being a relatively common issue, current conventional Western medicine (CWM) lacks effective, specific treatments for CSF. This leaves a significant unmet need for therapeutic options. Traditional Chinese Medicine (TCM) has a long history of use for cardiovascular ailments, and Shexiang Baoxin Pill (SXBXP) is a widely used TCM formulation in China that has shown promise in clinical studies for CSF. However, these studies are often small, single-center, and of varying quality, leading to inconclusive evidence. This paper aims to address this by systematically pooling the existing RCT data to provide a more robust assessment of SXBXP's efficacy and safety for CSF.
Methods
The researchers conducted a comprehensive systematic review and meta-analysis of randomized controlled trials (RCTs) identified from seven databases. To strengthen the analysis and account for potential biases, they employed two additional advanced statistical methods:
- Meta-analysis: This standard technique combines the results of multiple studies to produce a pooled estimate of the treatment effect, increasing statistical power and precision. They used both fixed-effect and random-effect models depending on the heterogeneity of the included studies.
- Trial Sequential Analysis (TSA): This method is used to determine if the accumulated evidence is sufficient to reach a reliable conclusion, even with a limited number of studies. It helps to avoid premature conclusions due to random error or small sample sizes.
- GRADE (Grades of Recommendation, Assessment, Development and Evaluation): This framework was used to assess the overall quality of the evidence for each outcome, classifying it as high, moderate, low, or very low. This helps to understand the reliability of the findings and guide clinical decision-making.
Datasets
The study did not introduce new datasets or benchmarks. Instead, it analyzed data from 10 previously published randomized controlled trials (RCTs) that met specific inclusion criteria for SXBXP's use in treating Coronary Slow Flow (CSF).
Key Insights and Ideas
- SXBXP shows promise in improving multiple aspects of CSF: The meta-analysis suggests that adding SXBXP to conventional treatment not only alleviates angina symptoms but also positively impacts key physiological markers related to blood flow and inflammation.
- The "small vessels" are crucial in CSF: The paper highlights that CSF is primarily related to issues in the smaller coronary arteries (<400 µm), which regulate myocardial blood flow. SXBXP's potential to improve microcirculation is a key area of interest.
- Mechanisms of action are being elucidated: The authors discuss how SXBXP's active components might work by promoting angiogenesis, improving endothelial function, and reducing inflammation, providing a scientific basis for its observed effects.
- Evidence quality is a major bottleneck: Despite positive trends in the meta-analysis, the low to very low GRADE ratings for most outcomes are a critical takeaway, underscoring the need for more rigorous research.
Key Results
The meta-analysis of 10 RCTs revealed several significant findings when comparing SXBXP combined with CWM versus CWM alone:
- Improved Angina Efficacy: SXBXP significantly improved angina pectoris efficacy (RR = 1.37, 95% CI [1.23, 1.52], p < 0.00001).
- Enhanced Blood Flow:
- Reduced mean corrected TIMI frame count (CTFC) (WMD = -4.23, 95% CI [-5.51, -2.95], p < 0.00001).
- Reduced CTFC in specific arteries: LAD (WMD = -6.36, p = 0.029), LCX (WMD = -5.73, p < 0.00001), and RCA (WMD = -6.72, p = 0.001).
- Reduced Positive Treadmill Exercise Test Rate: SXBXP decreased the incidence of positive treadmill exercise tests (RR = 0.45, 95% CI [0.25, 0.83], p = 0.010).
- Improved Biomarkers:
- Reduced Endothelin-1 (ET-1) levels (WMD = -11.03, 95% CI [-13.92, -8.14], p < 0.00001).
- Increased Nitric Oxide (NO) levels (WMD = 11.32, 95% CI [0.04, 22.59], p = 0.049).
- Reduced high-sensitivity C-reactive protein (hs-CRP) levels (WMD = -1.95, 95% CI [-2.57, -1.34], p < 0.00001).
- Reduced Adverse Reactions: The incidence of adverse reactions was lower in the SXBXP group (RR = 0.20, 95% CI [0.05, 0.85], p = 0.030).
- Trial Sequential Analysis (TSA): TSA affirmed the clinical efficacy of SXBXP for angina pectoris.
- GRADE Evidence Quality: Most outcomes were rated as low or very low quality evidence, with mean CTFC and hs-CRP being moderate quality.
Limitations and Future Work
The authors acknowledge several significant limitations:
- Poor Reporting Quality: Only two of the 10 included studies properly described randomization methods. Allocation concealment and blinding were not consistently reported across studies, introducing potential bias.
- Heterogeneity: While subgroup analyses were performed for CTFC, significant heterogeneity remained in some subgroups, suggesting other unmeasured factors might be at play.
- Limited Safety Data: Adverse reactions were reported in only two studies, which is insufficient to draw definitive conclusions about SXBXP's safety profile.
- Variability in CWM: The specific conventional Western medicine treatments used varied across studies, potentially contributing to heterogeneity.
- Lack of Long-Term Outcomes: The studies primarily focused on short-term efficacy and did not assess long-term cardiovascular events.
Future Work: The authors strongly recommend the need for more high-quality, large-scale, multicenter, placebo-controlled RCTs with rigorous designs and standardized protocols to definitively confirm the efficacy and safety of SXBXP for CSF. These future studies should adhere to CONSORT guidelines for improved reporting and include comprehensive assessment of both clinical outcomes and safety.
Summary updated